<unk>  symptoms manifest themselves as deficits in sensory, motor, and/or autonomic functions of varying intensity, and they can significantly reduce a patient's functional quality of life. Sensory symptoms affecting the hands and feet generally develop first. Sensory side effects are caused when nerves in the most distal parts of the limbs are damaged. Patients may experience numbness, tingling, altered touch sensation, gait and balance disturbances, burning pain, thermal allodynia or hyperalgesia, impaired vibration sense, extreme temperature sensitivity, paresthesia, and/or dysesthesia as part of sensory damage. On the other hand, motor symptoms are less frequently seen as sensory symptoms. Motor symptoms of<unk>  can include cramping, distal weakness, difficulty handling small objects, and impaired movements. In severe cases, motor symptoms can lead to complete immobilization and severe disability. Finally, autonomic symptoms usually involve orthostatic hypotension, constipation, and altered urinary function. A patient experiencing<unk>  symptoms may have difficulty performing daily functionalities like walking, dressing themselves, writing, typing, and other activities related to the hands and feet. The prevalence of these symptoms is highest in the first month after the completion of<unk>  at 68.1%, but as many as 30% of patients still report<unk>  symptoms six months after the completion of<unk> . Paclitaxel and oxaliplatin, representatives from two of the six major antineoplastic agents causing<unk> , cause acute neuropathy, which manifests during or immediately after treatment infusion. The other four groups of agents generally cause late symptoms that emerge weeks after the completion of<unk> . In both cases, the severity of the symptoms are generally proportional to the dose of the treatment drug received, and the severity of the symptoms may warrant a reduction in the<unk>  dosage. Pain and sensory abnormalities can persist for months or years after treatment completion. Some patients may experience “coasting,” where symptoms intensify after completion of treatment. As such, patients can be cancer-free and still suffer from disabling neuropathy<unk>  by cancer treatment.
Chemotherapy-induced peripheral neuropathy
Diabetic neuropathy
Tropical neuropathy
Progressive inflammatory neuropathy
Vasculitic neuropathy
Small fiber peripheral neuropathy
Alcoholic polyneuropathy
Chronic inflammatory demyelinating polyneuropathy